New drugs in preclinical and early stage clinical development in the treatment of heart failure-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

New drugs in preclinical and early stage clinical development in the treatment of heart failure

Published:2018-12-07 Issue:1 Volume:28 Page:51-71
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Tamargo Juan¹,Caballero Ricardo¹,Delpón Eva¹

Affiliation:

1. Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, CIBERCV, Madrid, Spain

Funder

Consejería de Educación, Juventud y Deporte, Comunidad de Madrid

Instituto de Salud Carlos III

Ministerio de Ciencia e Innovación

Sociedad Española de Cardiología

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2019.1551357

Reference195 articles.

1. Heart Disease and Stroke Statistics—2016 Update

2. Heart failure

3. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

4. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary

5. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The scientific targets: the myocardium, the vasculature and the body’s response to heart failure;Global Cardiology;2024-03-28

2. Targeting regulatory T cells for cardiovascular diseases;Frontiers in Immunology;2023-02-23

3. Natural bioactive products as promising therapeutics: A review of natural product-based drug development;South African Journal of Botany;2022-12

4. Non-Canonical Allostery in Cyclic Nucleotide Dependent Kinases;Journal of Molecular Biology;2022-09

5. LncRNA HOX transcript antisense RNA mitigates cardiac function injury in chronic heart failure via regulating microRNA‐30a‐5p to target KDM3A;Journal of Cellular and Molecular Medicine;2022-01-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3